CGRP-targeted therapy for migraine prophylaxis

Dr. Tepper describes the breakthrough of CGRP-targeted therapy for the prevention of migraine

Edvinsson L et al. Nat Rev Neurol. 2018;14:338-350. Marshall A. Neurol Rev 2018 (Suppl): S1-S8. Tepper SJ et al. Neurology. 2019;92:e1-e12.

Dr. Stewart J Tepper has working relationship with the companies listed: Accorda, Alder, Alexsa, Allergan, ATI, Alphasights, Amgen, Axsome, Biohaven, BioDelivery Sciences Intl, Cefaly, Charleston Labs, Decision Resources, CLG, Dr. Reddy's, ElectroCore, EliLilly, eNeuro, ExpertConnect, GSK, Guidepoint Global, Impel, M3 Global Research, Magellan Rx Mgmt, MedicXi, Novartis, Navigent Consulting, Neurolief, Pfizer, Nordy Biotech, Reckner Healthcare, Relevale, Satsuma, Scion Neurostim, Slingshot Insights, Sorrento, Sudler and Hennessey, Supernus, Teva, Theronica, Trinity Partners, XOC, Zosano